Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update

VEGA-3 Phase 3 Study of Phentolamine Ophthalmic Solution in Presbyopia is Recruiting Patients with Top-Line Data Expected in 2025

LYNX-2 Phase 3 Study of Phentolamine Ophthalmic Solution Continues Enrollment with Top-Line Data Expected in 2025

Read more at globenewswire.com